The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
Open accessAbstract
BACKGROUND: Type 1 diabetes (T1D) results from destruction of pancreatic β cells by autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would result in targeted quantitative and qualitative changes in effector T cells and prolonged preservation of endogenous insulin secretion by the remaining β cells in patients with newly diagnosed T1D. METHODS: In a multicenter, randomized, double-blind, placebo-controlled trial, we compared alefacept (two 12-week courses of 15 mg/wk i.m., separated by a 12-week pause) with placebo in patients with recent onset of T1D. Endpoints were assessed at 24 months and included meal-stimulated C-peptide AUC, insulin use, hypoglycemic events, and immunologic responses. RESULTS: A total of 49 patients were enrolled. At 24 months, or 15 months after the last dose of alefacept, both the 4-hour and the 2-hour C-peptide AUCs were significantly greater in the treatment group than in the control group (P = 0.002 and 0.015, respectively). Exogenous insulin requirements were lower (P = 0.002) and rates of major hypoglycemic events were about 50% reduced (P < 0.001) in the alefacept group compared with placebo at 24 months. There was no apparent between-group difference in glycemic control or adverse events. Alefacept treatment depleted CD4+ and CD8+ central memory T cells (Tcm) and effector memory T cells (Tem) (P < 0.01), preserved Tregs, increased the ratios of Treg to Tem and Tcm (P < 0.01), and increased the percentage of PD-1+CD4+ Tem and Tcm (P < 0.01). CONCLUSIONS: In patients with newly diagnosed T1D, two 12-week courses of alefacept preserved C-peptide secretion, reduced insulin use and hypoglycemic events, and induced favorable immunologic profiles at 24 months, well over 1 year after cessation of therapy. TRIAL REGISTRATION: https://clinicaltrials.gov/ NCT00965458. FUNDING: NIH and Astellas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572 · cited 1×
“Severe iatrogenic hypoglycemia is the most concerning risk of intensive management and leads to substantial morbidity and mortality in T1D (4, 29, 30).”
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Prevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009
Dabelea, D., Mayer-Davis, E. J., Saydah, S., Imperatore, G., Linder, B., Divers, J., Bell, R., Badaru, A., Talton, J. W., Crume, T., et al. (2014) · JAMA · doi:10.1001/jama.2014.3201 · Cited by 1,412
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“Severe iatrogenic hypoglycemia is the most concerning risk of intensive management and leads to substantial morbidity and mortality in T1D (4, 29, 30).”
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Self-citationGlycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408214 · Cited by 964
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Cited by
Autoreactive T cells in type 1 diabetes
Pugliese, A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94549 · Cited by 358
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308743 · Cited by 273
Self-citationNew frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
“Alefacept is an LFA3-Ig fusion protein that binds CD2, which predominates on these effector T cells (Rigby et al., 2015).”
BackgroundGolimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes
Quattrin, T., Haller, M. J., Steck, A. K., Felner, E. I., Li, Y., Xia, Y., Leu, J. H., Zoka, R., Hedrick, J. A., Rigby, M. R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006136 · Cited by 255
Self-citationWriting Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer, J. P., Schatz, D. A., Bundy, B., Skyler, J. S., & Greenbaum, C. J. (2017) · JAMA · doi:10.1001/jama.2017.17070 · Cited by 214
Self-citationRegulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it?
Hull, C. M., Peakman, M., & Tree, T. I. M. (2017) · Diabetologia · doi:10.1007/s00125-017-4377-1 · Cited by 194
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00019-x · Cited by 186
Self-citationHaller, M. J., Bell, K. J., Besser, R. E. J., Casteels, K., Couper, J. J., Craig, M. E., Elding Larsson, H., Jacobsen, L., Lange, K., Oron, T., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000543035 · Cited by 151
Changing the landscape for type 1 diabetes: the first step to prevention
Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N., & Herold, K. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32127-0 · Cited by 96
Bogun, M. M., Bundy, B. N., Goland, R. S., & Greenbaum, C. J. (2020) · Diabetes Care · doi:10.2337/dc19-2288 · Cited by 72
Self-citationLudvigsson, J., Sumnik, Z., Pelikanova, T., Nattero Chavez, L., Lundberg, E., Rica, I., Martínez-Brocca, M. A., Ruiz de Adana, M., Wahlberg, J., Katsarou, A., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0318 · Cited by 58
“The most efficient immune therapy evaluated to date for preservation of b-cell function is treatment with anti-CD3 monoclonal antibodies (teplizumab) (5,6); tumor necrosis factor-a inhibitors (7), ATG (8), alefacept (9), and rituximab (10) have also displayed efficacy, which is encouraging, but sometimes these therapi…”
BackgroundEvolving antibody therapies for the treatment of type 1 diabetes
Ke, Q., Kroger, C. J., Clark, M., & Tisch, R. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624568 · Cited by 44
T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases
McKinney, E. F., & Smith, K. G. (2016) · Immunology & Cell Biology · doi:10.1038/icb.2016.81 · Cited by 36
Latres, E., Greenbaum, C. J., Oyaski, M. L., Dayan, C. M., Colhoun, H. M., Lachin, J. M., Skyler, J. S., Rickels, M. R., Ahmed, S. T., Dutta, S., et al. (2024) · Diabetes · doi:10.2337/dbi23-0012 · Cited by 35
Self-citationIslet transplantation for hypoglycemia unawareness/severe hypoglycemia: caveat emptor
Harlan, D. M. (2016) · Diabetes Care · doi:10.2337/dci16-0008 · Cited by 25
Yang, J. H. M., Ward‐Hartstonge, K. A., Perry, D. J., Blanchfield, J. L., Posgai, A. L., Wiedeman, A. E., Diggins, K., Rahman, A., Tree, T. I. M., Brusko, T. M., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202049067 · Cited by 16
Self-citation
Metadata
- Authors
- Rigby, M. R., Harris, K. M., Pinckney, A., DiMeglio, L. A., Rendell, M. S., Felner, E. I., Dostou, J. M., Gitelman, S. E., Griffin, K. J., Tsalikian, E., Gottlieb, P. A., Greenbaum, C. J., Sherry, N. A., Moore, W. V., Monzavi, R., Willi, S. M., Raskin, P., Keyes-Elstein, L., Long, S. A., Kanaparthi, S., Lim, N., Phippard, D., Soppe, C. L., Fitzgibbon, M. L., McNamara, J., Nepom, G. T., Ehlers, M. R., & the Immune Tolerance Network (ITN) T1DAL Study Group
- Venue
- Journal of Clinical Investigation
- Published
- 2015-07-20
- Volume
- 125
- Issue
- 8
- Pages
- 3285-3296
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2106218189
- Cited by
- 291
- References
- 45
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.